NeuroPace (NPCE) Free Cash Flow Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.30 Bn | 175.00 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 128.77 Bn | 125.89 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 67.85 Bn | 66.39 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 48.12 Bn | 44.45 Bn | 1.29 Bn | -109.40% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 363.84% |
| 7 | GE HealthCare Technologies | 27.98 Bn | 25.70 Bn | 1.98 Bn | -31.71% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.78 Bn | 20.65 Bn | 2.07 Bn | 133.09% |
| 10 | NeuroPace | 520.59 Mn | 466.61 Mn | 18.05 Mn | 20.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.17% |
| Dec 31, 2025 | 109.05% |
| Sep 30, 2025 | -4.81% |
| Jun 30, 2025 | 44.65% |
| Mar 31, 2025 | 0.24% |
| Dec 31, 2024 | -33.61% |
| Sep 30, 2024 | 18.93% |
| Jun 30, 2024 | 8.22% |
| Mar 31, 2024 | 23.14% |
| Dec 31, 2023 | 58.22% |
| Sep 30, 2023 | 66.81% |
| Jun 30, 2023 | 60.48% |
| Mar 31, 2023 | 14.01% |
| Dec 31, 2022 | 6.05% |
| Sep 30, 2022 | -55.67% |
| Jun 30, 2022 | -82.55% |
| Mar 31, 2022 | -93.75% |
| Dec 31, 2021 | -31.20% |
| Sep 30, 2021 | 16.99% |
| Jun 30, 2021 | -84.91% |